SUBSCRIBE

Breaking News on Contract Research, Manufacturing & Clinical Trials

Read more breaking news

 

 
Loading...
Dispatches from interphex

Consolidation prevalent in industry, says third largest CMO

By Dan Stanton , 26-Mar-2014
Last updated on 26-Mar-2014 at 14:43 GMT

Aenova says the acquisition of Haupt Pharma and Patheon’s merger with DSM are evidence of consolidation in the CMO industry, as it looks to further increase its global footprint.

In the last few months the Aenova Group acquired Munich, Germany-headquartered Haupt Pharma , whilst Patheon closed its $2.65bn (€1.9bn) merger of DSM’s pharma division. Last week, Outsourcing-Pharma.com met up with Aenova’s VP of Marketing and Sales, Brad Carlson, at Interphex in New York to ask whether such acquisitions were demonstrative of the contract manufacturing industry as a whole.

“I think there is still a space for the small companies, but clearly there is a merger and acquisition trend going on in the larger companies,” Carlson told us, highlighting the Aenova and Patheon deals in such examples.

“We found this to be a very important strategy for our company, both [to increase] the global footprint and also the breadth of services.”

Top Three CMO

Carlson said Aenova was “now the third largest CMO in the world,” yet the Aenova Group only began life in 2008 when softgel company Swiss Caps and Dragenopharm – a maker of other solid dosage forms – combined.

Since then the company has added ointments, creams, liquids, and suppositories capabilities with the 2012 acquisition of the Temmler Group and, with Haupt, can now offer amongst other services, sterile injectables, freeze-drying, beta-lactams, and oral contraceptives.

 “[The] combination of these companies has given us essentially a full breadth of services and also a global footprint, matching ourselves up with, let’s say, Patheon and Catalent, the two largest CMOs.”

He continued: “We still have our eyes set on some additional items we’d like to do, markets we’d like to enter and so on, so I think you’ll continue to see this happening with our company as well as others.”

Future Growth and New Markets

Carlson said Aenova was still in growth mode, and whilst it would concentrate less on acquisitions focusing on dosage forms (as “we’ve covered the breadth of services pretty well,” he told us), new geographical markets would be the target.

“Our company is primarily based out of Europe,” he told us, with 19 of the firm’s 21 facilities located there. “I think you’ll see us expanding outside of that region in our facilities and acquisitions.”

Furthermore, whilst Aenova and CMOs generally are eying up areas such as Latin America and Australia, he said the North American market should not be omitted.

“The US market is the number one market for the consumer healthcare and pharma customers, so obviously the CMOs have to play in these markets.” However, he continued, “there is a tremendous amount of growth in Latin America, Asia-Pacific, Australia, where multinationals will have to go.”

Related products

Consolidation prevalent in industry, says third largest CMO

Consolidation prevalent in industry, says third largest CMO

Brad Carlson

VP Marketing 7 Sales, Aenova

Catalent commits to ADCs by upping its stake in Redwood

Catalent commits to ADCs by upping its stake in Redwood

Aileen Ruff

Global Strategic Marketing Director, Biologics and Sterile Technologies at Catalent...

Kemwell Talks Expansion and Approvals in India and the US

Kemwell Talks Expansion and Approvals in India and the US

Christian Ahlmark

Director of Corporate Development , Kemwell Biopharma

AMRI Exec Discusses 'New Bar' in FDA Enforcement

Following the completion of remediation efforts to deal with an FDA warning letter, Chris...

Happy holidays from William Reed Business Media!

Happy holidays from William Reed Business Media!

The working year is almost done, time to pause from ‘the business’ and embrace...

Aesica says academic partnerships are key for CMOs

Aesica says academic partnerships are key for CMOs

Alan Raymond

Sales & Marketing Director, Aesica Pharmaceuticals

Wockhardt targets CMO space for diversification

Wockhardt targets CMO space for diversification

Tom Salus

Associate Vice President, Business Development - Contract Services, Wockhardt

Kemwell and Boehringer set to finish biologics plant in India

Kemwell and Boehringer set to finish biologics plant in India

Christian Ahlmark

Director of corporate development , Kemwell

A bitter pill to swallow: young people dislike tablets more than old

A bitter pill to swallow: young people dislike tablets more than old

Thomas Hein

Director, Sales & Business Development, Hermes

Kemwell CEO says environmental efforts are worth the cost

Kemwell CEO says environmental efforts are worth the cost

Kemwell CEO Agneta Bergvall says drugmakers' efforts to make pharmaceutical manufacturing green are worth...

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Catalent launches softgel products at CPhI: one vegetarian, one anti-abuse

Will Downie

Senior VP Global Vusiness Development & Marketing, Catalent

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

AlpVision's iPhone Tech Offers Authentication in War on Counterfeits

Quincy Mattingly

Regional Manager, AlpVision

Cobra Biologics talks recent fill finish acquisition and future growth plans

Cobra Biologics talks recent fill finish acquisition and future growth plans

Philip Ridley-smith

Business Development & Marketing Manager, Cobra Biologics

Catalent says sharing with industry will not dull competetive edge

Catalent says sharing with industry will not dull competetive edge

Kurt Nielsen and Cornell Stamoran

Various, Catalent

Bend Research hunting new partnerships to boost bioavailability offering

Bend Research hunting new partnerships to boost bioavailability offering

David Lyon and Karen Coppens

Various, Bend Research and Dow

Changes to EU clinical trial laws will mean fairer playing field, says Clinipace

Changes to EU clinical trial laws will mean fairer playing field, says Clinipace

Andrea Schiefer

VP of European clinical operations and executive director of pharmacovigilance,...